Infectious Diseases in Obstetrics and Gynecology
Volume 2009 (2009), Article ID 653598, 9 pages
doi:10.1155/2009/653598
Research Article

HPV Prevalence in Colombian Women with Cervical Cancer: Implications for Vaccination in a Developing Country

Raúl Murillo,1 Mónica Molano,2 Gilberto Martínez,3 Juan-Carlos Mejía,4 and Oscar Gamboa1

1Subdirección Investigaciones, Instituto Nacional de Cancerología de Colombia, Bogota, Colombia
2Grupo Investigación en Biología del Cáncer, Instituto Nacional de Cancerología de Colombia, Colombia
3Ginecólogo Oncólogo, Clínica del Country de Bogotá, Colombia
4Patología, Instituto Nacional de Cancerología de Colombia, Colombia

Received 3 June 2009; Revised 8 September 2009; Accepted 9 October 2009

Academic Editor: Diane Harper

Copyright © 2009 Raúl Murillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005.
  2. J. M. M. Walboomers, M. V. Jacobs, M. M. Manos, et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” Journal of Pathology, vol. 189, no. 1, pp. 12–19, 1999. View at Publisher · View at Google Scholar
  3. E. L. Franco, V. Tsu, R. Herrero, et al., “Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean,” Vaccine, vol. 26, supplement 11, pp. L88–L95, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. L. L. Villa, R. L. R. Costa, C. A. Petta, et al., “High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up,” British Journal of Cancer, vol. 95, no. 11, pp. 1459–1466, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. D. M. Harper, E. L. Franco, C. M. Wheeler, et al., “Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial,” The Lancet, vol. 367, no. 9518, pp. 1247–1255, 2006. View at Publisher · View at Google Scholar · View at PubMed
  6. G. Clifford, S. Franceschi, M. Diaz, N. Muñoz, and L. L. Villa, “Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases,” Vaccine, vol. 24, supplement 3, pp. S26–S34, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. J. M. Agosti and S. J. Goldie, “Introducing HPV vaccine in developing countries—key challenges and issues,” The New England Journal of Medicine, vol. 356, no. 19, pp. 1908–1910, 2007. View at Publisher · View at Google Scholar · View at PubMed
  8. S. J. Goldie, M. Diaz, D. Constenla, N. Alvis, J. K. Andrus, and S.-Y. Kim, “Mathematical models of cervical cancer prevention in Latin America and the Caribbean,” Vaccine, vol. 26, supplement 11, pp. L59–L72, 2008. View at Publisher · View at Google Scholar · View at PubMed
  9. G. M. Clifford, J. S. Smith, M. Plummer, N. Muñoz, and S. Franceschi, “Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis,” British Journal of Cancer, vol. 88, no. 1, pp. 63–73, 2003. View at Publisher · View at Google Scholar · View at PubMed
  10. J. T. Schiller, X. Castellsagué, L. L. Villa, and A. Hildesheim, “An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results,” Vaccine, vol. 26, supplement 10, pp. K53–K61, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. M. Piñeros, J. Ferlay, and R. Murillo, “Cancer incidence estimates at the national and district levels in Colombia,” Salud Publica de Mexico, vol. 48, no. 6, pp. 455–465, 2006.
  12. R. Murillo, M. Piñeros, and G. Hernández, Atlas de Mortalidad por Cáncer en Colombia, Instituto Nacional de Cancerología-Instituto Geográfico Agustín Codazzi, Bogotá, Colombia, 2004.
  13. F. A. Tavassoli and V. Ville, Eds., WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs, IARC Press, Lyon, France, 2003.
  14. A. M. de Roda Husman, J. M. M. Walboomers, E. Hopman, et al., “HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern,” Journal of Medical Virology, vol. 46, no. 2, pp. 97–102, 1995. View at Publisher · View at Google Scholar
  15. M. V. Jacobs, P. J. F. Snijders, A. J. C. van den Brule, T. J. M. Helmerhorst, C. J. L. M. Meijer, and J. M. M. Walboomers, “A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings,” Journal of Clinical Microbiology, vol. 35, no. 3, pp. 791–795, 1997.
  16. A. J. C. van den Brule, R. Pol, N. Fransen-Daalmeijer, L. M. Schouls, C. J. L. M. Meijer, and P. J. F. Snijders, “GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes,” Journal of Clinical Microbiology, vol. 40, no. 3, pp. 779–787, 2002. View at Publisher · View at Google Scholar
  17. N. Muñoz, F. X. Bosch, X. Castellsagué, et al., “Against which human papillomavirus types shall we vaccinate and screen? The international perspective,” International Journal of Cancer, vol. 111, no. 2, pp. 278–285, 2004. View at Publisher · View at Google Scholar · View at PubMed
  18. C. Särndal, B. Swensson, and J. Wretman, Model Assisted Survey Sampling, Springer, New York, NY, USA, 1997.
  19. N. Muñoz, F. X. Bosch, S. de Sanjoseé, et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003. View at Publisher · View at Google Scholar · View at PubMed
  20. J. S. Smith, L. Lindsay, B. Hoots, et al., “Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update,” International Journal of Cancer, vol. 121, no. 3, pp. 621–632, 2007. View at Publisher · View at Google Scholar · View at PubMed
  21. F. X. Bosch, A. N. Burchell, M. Schiffman, et al., “Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia,” Vaccine, vol. 26, supplement 10, pp. K1–K16, 2008. View at Publisher · View at Google Scholar · View at PubMed
  22. W. Qu, G. Jiang, Y. Cruz, et al., “PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems,” Journal of Clinical Microbiology, vol. 35, no. 6, pp. 1304–1310, 1997.
  23. J. Paavonen, D. Jenkins, F. X. Bosch, et al., “Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial,” The Lancet, vol. 369, no. 9580, pp. 2161–2170, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. R. López-Revilla, L. A. Martínez-Contreras, and M. Sánchez-Garza, “Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma,” Infectious Agents and Cancer, vol. 3, article 3, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. C. Santos, N. Muñoz, S. Klug, et al., “HPV types and cofactors causing cervical cancer in Peru,” British Journal of Cancer, vol. 85, no. 7, pp. 966–971, 2001. View at Publisher · View at Google Scholar · View at PubMed
  26. P. A. Rolón, J. S. Smith, N. Muñoz, et al., “Human papillomavirus infection and invasive cervical cancer in Paraguay,” International Journal of Cancer, vol. 85, no. 4, pp. 486–491, 2000. View at Publisher · View at Google Scholar
  27. D. M. Harper, “Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials,” Therapy, vol. 5, no. 3, pp. 313–324, 2008. View at Publisher · View at Google Scholar
  28. M. Stanley, L. Gissmann, and D. Nardelli-Haefliger, “Immunobiology of human papillomavirus infection and vaccination—implications for second generation vaccines,” Vaccine, vol. 26, supplement 10, pp. K62–K67, 2008. View at Publisher · View at Google Scholar · View at PubMed